133 related articles for article (PubMed ID: 32998194)
21. Short, full-dose adjuvant chemotherapy (CT) in high-risk adult soft tissue sarcomas (STS): long-term follow-up of a randomized clinical trial from the Italian Sarcoma Group and the Spanish Sarcoma Group.
Gronchi A; Stacchiotti S; Verderio P; Ferrari S; Martin Broto J; Lopez-Pousa A; Llombart-Bosch A; Dei Tos AP; Collini P; Jurado JC; De Paoli A; Donati DM; Poveda A; Quagliuolo V; Comandone A; Grignani G; Morosi C; Messina A; De Sanctis R; Bottelli S; Palassini E; Casali PG; Picci P
Ann Oncol; 2016 Dec; 27(12):2283-2288. PubMed ID: 27733375
[TBL] [Abstract][Full Text] [Related]
22. The classic prognostic factors tumor stage, tumor size, and tumor grade are the strongest predictors of outcome in synovial sarcoma: no role for SSX fusion type or ezrin expression.
ten Heuvel SE; Hoekstra HJ; Bastiaannet E; Suurmeijer AJ
Appl Immunohistochem Mol Morphol; 2009 May; 17(3):189-95. PubMed ID: 18997619
[TBL] [Abstract][Full Text] [Related]
23. Five-year results in Ewing's sarcoma. The Scandinavian Sarcoma Group experience with the SSG IX protocol.
Elomaa I; Blomqvist CP; Saeter G; Akerman M; Stenwig E; Wiebe T; Björk O; Alvegård TA
Eur J Cancer; 2000 May; 36(7):875-80. PubMed ID: 10785592
[TBL] [Abstract][Full Text] [Related]
24. Outcome of chemotherapy in advanced synovial sarcoma patients: Review of 15 clinical trials from the European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group; setting a new landmark for studies in this entity.
Vlenterie M; Litière S; Rizzo E; Marréaud S; Judson I; Gelderblom H; Le Cesne A; Wardelmann E; Messiou C; Gronchi A; van der Graaf WT
Eur J Cancer; 2016 May; 58():62-72. PubMed ID: 26968015
[TBL] [Abstract][Full Text] [Related]
25. Long-term follow-up of patients treated with neoadjuvant chemotherapy and radiotherapy for large, extremity soft tissue sarcomas.
Mullen JT; Kobayashi W; Wang JJ; Harmon DC; Choy E; Hornicek FJ; Rosenberg AE; Chen YL; Spiro IJ; DeLaney TF
Cancer; 2012 Aug; 118(15):3758-65. PubMed ID: 22180344
[TBL] [Abstract][Full Text] [Related]
26. [Evaluation of prognostic factors for synovial sarcoma].
Du ZY; Guo W; Yang RL; Yan TQ; Li DS
Zhonghua Wai Ke Za Zhi; 2011 Nov; 49(11):991-4. PubMed ID: 22333419
[TBL] [Abstract][Full Text] [Related]
27. Long-term Follow-up and Post-relapse Outcome of Patients with Localized Retroperitoneal Sarcoma Treated in the Italian Sarcoma Group-Soft Tissue Sarcoma (ISG-STS) Protocol 0303.
De Sanctis R; Giordano L; Colombo C; De Paoli A; Navarria P; Sangalli C; Buonadonna A; Sanfilippo R; Bertola G; Fiore M; Marrari A; Navarria F; Bertuzzi A; Casali PG; Basso S; Santoro A; Quagliuolo V; Gronchi A
Ann Surg Oncol; 2017 Dec; 24(13):3872-3879. PubMed ID: 29043525
[TBL] [Abstract][Full Text] [Related]
28. Long-term Outcomes With Ifosfamide-based Hypofractionated Preoperative Chemoradiotherapy for Extremity Soft Tissue Sarcomas.
Pennington JD; Eilber FC; Eilber FR; Singh AS; Reed JP; Chmielowski B; Eckardt JJ; Bukata SV; Bernthal NM; Federman N; Nelson SD; Dry SM; Wang PC; Luu M; Selch MT; Steinberg ML; Kalbasi A; Kamrava M
Am J Clin Oncol; 2018 Dec; 41(12):1154-1161. PubMed ID: 29664796
[TBL] [Abstract][Full Text] [Related]
29. The impact of chemotherapy on survival of patients with extremity and trunk wall soft tissue sarcoma: revisiting the results of the EORTC-STBSG 62931 randomised trial.
Pasquali S; Pizzamiglio S; Touati N; Litiere S; Marreaud S; Kasper B; Gelderblom H; Stacchiotti S; Judson I; Dei Tos AP; Verderio P; Casali PG; Woll PJ; Gronchi A;
Eur J Cancer; 2019 Mar; 109():51-60. PubMed ID: 30690293
[TBL] [Abstract][Full Text] [Related]
30. Superficial soft tissue sarcomas (S-STS): a study of 367 patients from the French Sarcoma Group (FSG) database.
Salas S; Stoeckle E; Collin F; Bui B; Terrier P; Guillou L; Trassard M; Ranchere-Vince D; Gregoire F; Coindre JM
Eur J Cancer; 2009 Aug; 45(12):2091-102. PubMed ID: 19351580
[TBL] [Abstract][Full Text] [Related]
31. Efficacy of radio-hyperthermo-chemotherapy as salvage therapy for recurrent or residual malignant soft tissue tumors.
Aiba H; Yamada S; Mizutani J; Yamamoto N; Okamoto H; Hayashi K; Takeuchi A; Miwa S; Higuchi T; Abe K; Taniguchi Y; Tsuchiya H; Otsuka T
Int J Hyperthermia; 2018; 35(1):658-666. PubMed ID: 30295115
[TBL] [Abstract][Full Text] [Related]
32. Response to neoadjuvant chemotherapy combined with regional hyperthermia predicts long-term survival for adult patients with retroperitoneal and visceral high-risk soft tissue sarcomas.
Wendtner CM; Abdel-Rahman S; Krych M; Baumert J; Lindner LH; Baur A; Hiddemann W; Issels RD
J Clin Oncol; 2002 Jul; 20(14):3156-64. PubMed ID: 12118030
[TBL] [Abstract][Full Text] [Related]
33. Predictive and prognostic factors associated with soft tissue sarcoma response to chemotherapy: a subgroup analysis of the European Organisation for Research and Treatment of Cancer 62012 study.
Young RJ; Litière S; Lia M; Hogendoorn PCW; Fisher C; Mechtersheimer G; Daugaard S; Sciot R; Collin F; Messiou C; Grünwald V; Gronchi A; van der Graaf W; Wardelmann E; Judson I
Acta Oncol; 2017 Jul; 56(7):1013-1020. PubMed ID: 28431480
[TBL] [Abstract][Full Text] [Related]
34. Assessing the Role of Neoadjuvant Chemotherapy in Primary High-Risk Truncal/Extremity Soft Tissue Sarcomas: An Analysis of the Multi-institutional U.S. Sarcoma Collaborative.
Zaidi MY; Ethun CG; Tran TB; Poultsides G; Grignol VP; Howard JH; Bedi M; Mogal H; Tseng J; Roggin KK; Chouliaras K; Votanopoulos K; Krasnick B; Fields RC; Oskouei S; Reimer N; Monson D; Maithel SK; Cardona K
Ann Surg Oncol; 2019 Oct; 26(11):3542-3549. PubMed ID: 31342400
[TBL] [Abstract][Full Text] [Related]
35. Adjuvant chemotherapy-Radiotherapy-Chemotherapy sandwich protocol in resectable soft tissue sarcoma: An updated single-center analysis of 104 cases.
Schliemann C; Kerkhoff A; Hesse P; Bröckling S; Hardes J; Streitbürger A; Andreou D; Gosheger G; Elges S; Wardelmann E; Hartmann W; Mesters R; Lenz G; Willich N; Kriz J; Eich H; Berdel WE; Kessler T
PLoS One; 2018; 13(5):e0197315. PubMed ID: 29787570
[TBL] [Abstract][Full Text] [Related]
36. Doxorubicin-based adjuvant chemotherapy in soft tissue sarcoma: pooled analysis of two STBSG-EORTC phase III clinical trials.
Le Cesne A; Ouali M; Leahy MG; Santoro A; Hoekstra HJ; Hohenberger P; Van Coevorden F; Rutkowski P; Van Hoesel R; Verweij J; Bonvalot S; Steward WP; Gronchi A; Hogendoorn PCW; Litiere S; Marreaud S; Blay JY; Van Der Graaf WTA
Ann Oncol; 2014 Dec; 25(12):2425-2432. PubMed ID: 25294887
[TBL] [Abstract][Full Text] [Related]
37. Prognostic variables for the selection of patients with operable soft tissue sarcomas to be considered in adjuvant chemotherapy trials.
Ravaud A; Bui NB; Coindre JM; Lagarde P; Tramond P; Bonichon F; Stöckle E; Kantor G; Trojani M; Chauvergne J
Br J Cancer; 1992 Nov; 66(5):961-9. PubMed ID: 1419644
[TBL] [Abstract][Full Text] [Related]
38. [Responses of 109 adult soft tissue sarcoma patients to chemotherapy].
Qiu MZ; Xu F; Wang SS; Luo HY; Wang F; Li FH; Sun XF; Xu GC; Lin TY; Huang HQ; Jiang WQ; Guan ZZ; Xu RH
Ai Zheng; 2007 Dec; 26(12):1344-9. PubMed ID: 18076798
[TBL] [Abstract][Full Text] [Related]
39. Perioperative chemotherapy with ifosfamide and doxorubicin for high-grade soft tissue sarcomas in the extremities (JCOG0304).
Tanaka K; Mizusawa J; Fukuda H; Araki N; Chuman H; Takahashi M; Ozaki T; Hiruma T; Tsuchiya H; Morioka H; Hatano H; Iwamoto Y
Jpn J Clin Oncol; 2015 Jun; 45(6):555-61. PubMed ID: 25838293
[TBL] [Abstract][Full Text] [Related]
40. High-dose ifosfamide as second- or third-line chemotherapy in refractory bone and soft tissue sarcoma patients.
Lee SH; Chang MH; Baek KK; Han B; Lim T; Lee J; Park JO
Oncology; 2011; 80(3-4):257-61. PubMed ID: 21734417
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
